- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02175589
Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The diagnosis of FMF is mainly clinical and genetic tests are only used to confirm the diagnosis . Even though the disease is autosomal recessive, not all FMF patients have two recognizable MEFV mutations. The phenotype of FMF patients varies according to the genotype, as shown by a number of studies showing that patients with one MEFV mutation have milder disease or even no symptoms. Some of the previously mentioned studies have shown that ceasing colchicine prophylaxis in these patients caused no recurrence. So far, no prospective controlled study has tested the effect of colchicine cessation in this group of FMF patients. The investigators presume that asymptomatic FMF patients with a single mutation can stop regular colchicine treatment while remaining under close follow-up.
The purpose of the work:
To examine the effect of colchicine cessation in a defined group of asymptomatic FMF patients with a single mutation in MEFV gene.
Methods and study population:
The work will be a controlled prospective comparative study including FMF patients aged 2-18 years. Patients included will be those who were asymptomatic for six months prior to entering the study and were regularly treated with colchicine, and with a normal serum level of Serum Amyloid A (SAA). The study group will include patients with a single MEFV mutation that will stop colchicine therapy, and the control group will include FMF who will continue regular colchicine treatment. Follow-up in both groups will include clinical and laboratory (serum SAA levels) evaluation.
The study end points and renewal of the colchicine:
Any patient that develops acute symptoms of FMF will be immediately invited to the rheumatology clinic for medical examination. In addition, patients will be invited to the clinic after 3 and 6 months from the beginning of the study. At any clinic visit (scheduled or not) the patients will be assessed clinically and laboratory (serum SAA levels). The study will be stopped and colchicine will be renewed if at any of the above mentioned clinic visit the patient will be diagnosed as having a classic FMF attack or the SAA level will be above 10 mg / l.
The importance of the study:
If the investigators conclude that colchicine prophylaxis can be safely discontinued in this group of FMF patients this will save them a treatment currently defined as a treatment for life.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Haifa, Israel
- Pediatric rheumatology clinic, Rambam Medical Center
-
Petach Tikva, Israel
- Schneider Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with FMF based on clinical criteria
- FMF patients diagnosed of having at least one common MEFV mutation will be assigned to the study group. FMF patients who staid on colchicine treatment will be assigned to the control group, regardless of their genotype.
- Patients who were on a continuous colchicine prophylactic treatment for six months prior to entering the study.
- FMF patients who were free of acute FMF symptoms for six months prior to entering th study
- Patients were included in the study only if they had normal serum level of SAA (up to 10 mg / l).
Exclusion Criteria:
- Patients that in the six months prior to entering the study continued to have classic FMF episodes despite being on a continuous prophylactic colchicine
- Patients that had high level of SAA (above 10 mg/l) despite being on prophylactic colchicine treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Study group
Colchicine Cessation in FMF patients with one MEFV mutation
|
Colchicine Cessation
|
No Intervention: Control group
The control group includes FMF patients that will be kept on a daily colchicine treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute clinical episode of FMF
Time Frame: 6 months
|
Acute clinical episode of FMF diagnosed by one of the investigators at any clinic visit assigned at 3 or 6 months after the cessation of colchicine treatment or at an unassigned visit if the patient attained the clinic due to an acute symptoms of FMF
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
High level of Serum Amyloid A (SAA) in serum
Time Frame: 6 months
|
High level of SAA (above 10 mg/l) at any clinic visit assigned at 3 or 6 months after the cessation of colchicine treatment or at an unassigned visit if the patient attained the clinic due to an acute symptoms of FMF
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Yonatan Butbul, MD, Rambam Health Care Campus
- Principal Investigator: Riva Brik, MD, Rambam Health Care Campus
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Wounds and Injuries
- Genetic Diseases, Inborn
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Skin Diseases, Genetic
- Body Temperature Changes
- Heat Stress Disorders
- Hyperthermia
- Fever
- Brucellosis
- Familial Mediterranean Fever
- Hereditary Autoinflammatory Diseases
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Gout Suppressants
- Colchicine
Other Study ID Numbers
- 0080-14-RMB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Familial Mediterranean Fever
-
Rambam Health Care CampusWithdrawnFamilial Mediterranean Fever (FMF )
-
Novartis PharmaceuticalsCompletedColchicine Resistant/Intolerant Familial Mediterranean FeverIsrael
-
National Human Genome Research Institute (NHGRI)Merck Sharp & Dohme LLC; Duke University; University of Massachusetts, WorcesterRecruitingFever | Genetic Diseases | Familial Mediterranean Fever (FMF) | Autoinflammation | Periodic Fever | ROSAH | ALPK1United States
-
University of PalermoCompletedFamilial Mediterranean Fever (FMF) | Not-celiac Wheat Sensitivity (NCWS)Italy
-
University Hospital, MontpellierNot yet recruitingFamilial Mediterranean FeverFrance
-
Sohag UniversityNot yet recruitingFamilial Mediterranean FeverEgypt
-
Aristea Therapeutics, Inc.WithdrawnFamilial Mediterranean FeverIsrael, Turkey
-
University Hospital TuebingenCompleted
-
Novartis PharmaceuticalsCompletedFamilial Mediterranean FeverTurkey
-
Sheba Medical CenterUnknownFamilial Mediterranean FeverIsrael
Clinical Trials on Colchicine Cessation
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR)CompletedAtrial Fibrillation | Thoracic SurgeryCanada
-
Population Health Research InstituteRecruitingInflammation | Peripheral Arterial Disease | Atherosclerosis of ExtremitiesCanada
-
Wuhan Union Hospital, ChinaCompletedCoronary Artery Disease | Percutaneous Coronary InterventionChina
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedObesity | Metabolic DiseaseUnited States
-
Tata Memorial HospitalUnknown
-
Central South UniversityJohns Hopkins Bloomberg School of Public Health; Purdue UniversityCompletedSmoking Cessation
-
Oregon Research Behavioral Intervention Strategies...RecruitingTobacco UseUnited States
-
The University of Hong KongCompletedSmoking CessationHong Kong
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
University of California, BerkeleyCompleted